The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Caldarone, B. J.; Paterson, N. E.; Zhou, J.; Brunner, D.; Kozikowski, A. P.; Westphal, K. G.; Korte-Bouws, G. A.; Prins, J.; Korte, S. M.; Olivier, B.; Ghavami, A

J Pharmacol Exp Ther 2010, 335, 762-70.